Participated · Series B · Jun 2026

Founded in 2024 by Shay Levi, Larissa Schneider, and Adi Azarya, Unframe provides a managed delivery model and an open platform called The Framery to implement enterprise AI solutions rapidly. Its approach pairs core platform components with hands-on delivery so solutions can run in a customer's cloud, on-premises, or as a managed SaaS offering without tying customers to a single large language model. Commercially, Unframe reached $100 million in total contract value within its first twelve months and reported 400% net revenue retention, with roughly half of customers converting to paid contracts under an outcome-based pricing model. The company employs about 120 people across Cupertino, Tel Aviv, and Berlin. Near-term plans announced alongside the Series B include expanding delivery capacity, investing further in The Framery, and adding senior leadership to support growth.

Participated · Series D · Mar 2022

ConsenSys develops core Ethereum infrastructure and consumer products, most notably the MetaMask wallet and the Infura developer platform, alongside Truffle, PegaSys and Codefi. Its products serve both developers and end users across the Ethereum ecosystem; MetaMask has over 30 million monthly active users and Infura reports 430,000 developers, with its API supporting over $1 trillion in annualized on‑chain ETH transaction volume. The company reported “nine figures” in revenue in 2021. ConsenSys plans to use new funding to grow its team from about 700 to roughly 1,000 by year‑end and to expand product capabilities, including a plug‑in extensibility system to integrate other protocols and pursue multi‑chain scalability. The firm completed a 2020 reorganization that moved assets from ConsenSys Mesh into ConsenSys Software Inc. and was founded in 2014. That asset transfer is the subject of shareholder allegations alleging improper shifts of assets and a group is pushing for an independent audit in Switzerland; ConsenSys Mesh says it expects any audit to confirm fair market value. ConsenSys builds Web3 infrastructure and developer tools, anchored by MetaMask (a self-custodial wallet) and Infura (developer node and API services). MetaMask serves approximately 21 million monthly active users who interact with roughly 3,700 unique Web3 applications, and its in-app swap feature has enabled more than $10 billion in token swaps. Infura is used by about 350,000 developers, and ConsenSys integrates other products (Truffle, Diligence, Customer Success) to support the full development lifecycle. The company supports many Ethereum-compatible Layer 2 networks, and MetaMask Institutional offers custody and compliance solutions for organizations accessing DeFi. ConsenSys Quorum Blockchain Service is used in 10 central bank digital currency projects worldwide. The firm says funding will expand MetaMask and Infura and add 400 new roles across products and services. ConsenSys’ engineering teams are also contributing to Ethereum’s upcoming merge to Proof of Stake. ConsenSys develops a suite of Ethereum products and developer tools including Codefi, Diligence, Infura, MetaMask, Truffle and Quorum. The company serves public and private permissioned networks, supports Layer 2 solutions and provides access to adjacent protocols such as IPFS and Filecoin. It restructured into two arms — ConsenSys (the core software business) and ConsenSys Mesh (the investment arm and incubator) — and acquired J.P. Morgan’s Quorum to deepen its enterprise offering. ConsenSys is a major contributor to Ethereum 2.0 and its Protocols group is building CBDCs for six central banks. Product usage metrics cited in the articles include MetaMask with more than 3 million monthly active users (a roughly 3x increase in five to six months), $1.8 billion in decentralized exchange swap volume (ConsenSys takes a 0.875% cut on swaps), Infura with over 150,000 developer users, and Truffle used by 4.5 million developers. ConsenSys develops blockchain solutions built on the Ethereum blockchain for a range of users, from local communities to global enterprises. The company provides enterprise and community-facing blockchain tools and services. The article reports a $10 million investment from SK Group. ConsenSys' technology focus and partnerships position it to support mobile identity and other enterprise blockchain use cases. No operating metrics (revenue or user counts) are provided in the article.

Participated · Series D · Nov 2021

Cambridge Epigenetix is a commercial-stage life sciences tools and technology company developing a proprietary genetic and epigenetic sequencing platform. Its first product identifies five letters of DNA—A, T, C, G and methylated cytosine (5mC/5hmC)—in a single sequencing workflow and integrates with existing sequencers. The technology requires low DNA input, aims to increase data quality and reduce sequencing costs, and combines laboratory kits with software. Manufacturing of the first product is underway with expected commercial availability in early 2022, and the company plans additional platform products including a six-letter kit. Early access programs with leading genomic research institutions are ongoing and have validated the technology. Proceeds from recent financing will be used to commercialize the platform and expand the organization. The company is based in Cambridge, United Kingdom, and was founded by Professor Sir Shankar Balasubramanian. Cambridge Epigenetix (CEGX) builds a proprietary discovery platform to affordably and accurately identify hydroxymethylated (5hmC) DNA from blood and tissue samples. The platform is aimed at earlier cancer diagnosis, improved patient stratification, and the development of liquid biopsy–based tests. CEGX intends to simplify several routine diagnostic screening tests to a simple blood draw as patients’ epigenetic codes change over time. The company spun out of the University of Cambridge in 2012 and was co-founded by Sir Shankar Balasubramanian and Dr Bobby Yerramilli-Rao. Jason Mellad, PhD, serves as CEO and has emphasized that the funding will support transforming patient care and making testing routine. CEGX has attracted investment from world-leading investors including Ahren, Sequoia, GV, New Sciences Ventures and Syncona. Cambridge Epigenetix is a U.K.-based Cambridge University spin-out that develops DNA modification analysis tools for epigenetics researchers. Its core products enable analysis of epigenetic marks to study how environmental and behavioral factors regulate gene expression without changing underlying DNA. The company positions the epigenome as holding potential similar to the commercialization of genome sequencing for improving human health. CEO Dr Geoff Smith highlighted the new investors' expertise in building data-driven businesses. The team and investors frame more accurate epigenetic data as foundational to future quantified health tracking and research applications. The company recently raised a $21M Series B to support commercialization and further development of its tools.

Participated · Series B · Sep 2021

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory diseases and autoimmune disorders. Its clinical-stage pipeline includes VTX958 (a Phase 1 allosteric TYK2 inhibitor), VTX002 (a Phase 2‑ready S1P1 receptor modulator for ulcerative colitis), and VTX2735 (a Phase 1‑ready peripheral NLRP3 inflammasome inhibitor). The company announced key leadership appointments, including Sheila Gujrathi as Executive Chair and Jörn Drappa as Chief Medical Officer, and added Luisa Salter-Cid and William White to its advisory and board roles. Ventyx says proceeds from its recent financing will strengthen its cash position and accelerate development of its clinical programs. The company is headquartered in Encinitas, California, and is focused on advancing its pipeline toward clinical development milestones. Ventyx Biosciences, based in Encinitas, California, is a clinical-stage biotech advancing a pipeline of potent and selective small-molecule drug candidates for inflammatory and autoimmune diseases. Its internally discovered, wholly-owned portfolio targets gastrointestinal and dermatological indications and combines clinical-stage programs from three companies founded by Raju Mohan and New Science Ventures. Key programs include a tissue-selective S1P1R modulator for IBD (from Oppilan Pharma), a selective allosteric TYK2 inhibitor developed by Ventyx, and an NLRP3 inhibitor program created by Zomagen whose first candidate is slated to enter the clinic in the second half of the year. Ventyx is also leveraging its drug discovery engine to advance preclinical programs against other biologically relevant targets. The company plans to use the $114M financing to fund clinical development of its immunology programs and to advance preclinical programs against novel targets. Led by CEO Raju Mohan, Ventyx emphasizes internal discovery and a broad immunology-focused pipeline.

Led · Series E · Jul 2021

BlockFi is a crypto financial-services firm that operates a platform holding client balances across account types. Amid a broad decline in crypto markets, BlockFi signed a term sheet for a $250 million revolving credit facility from FTX to backstop the firm and stabilize its balance sheet. CEO Zac Prince said the facility is intended to be contractually subordinated to all client balances and will bolster the firm's balance sheet and platform strength. FTX CEO Sam Bankman‑Fried said the partnership is meant to help BlockFi "navigate the market from a position of strength" and emphasized protecting customer assets. The term sheet is contingent on execution of definitive documents, which both companies expect to complete in the coming days. Company statements said operations remain normal and the funding should remove concerns about BlockFi's ability to service clients and temper worries about crypto contagion. BlockFi’s core product includes the BlockFi Interest Account (BIA), which promises high interest payouts to crypto depositors and had amassed over $15 billion in assets by March 31. The company is pursuing plans to go public, with investor materials indicating a 12-to-18-month timeline for an IPO. BlockFi is nearing a $500 million Series E that documents show is expected to close on July 27 and to leave the firm with a $4.75 billion post-money valuation. The Series E is being led by Hedosophia and Third Point LLC, with participation from Coinbase Ventures, Tiger Global and Bain Capital. At the same time, state regulators in Texas, Alabama and New Jersey have alleged the BIA is an unregistered security, prompting notices and deadlines that could affect onboarding and product operations. BlockFi’s leadership says it is engaging with regulators and believes the BIA is lawful while it continues to pursue growth and public-market plans. BlockFi offers a retail and institutional-facing suite of products that let users earn yield on crypto (6% on Bitcoin, 8.6% on stablecoins), buy and sell digital assets, and obtain low-cost loans secured by crypto holdings. The company also provides lending and trade execution services to institutions participating in digital-asset markets. BlockFi has seen rapid growth in users and assets: it now has 265,000 funded retail clients, over 200 institutional clients, and has lent over $10 billion. Assets on the platform rose to $15 billion (from $1 billion the prior March), while monthly revenue increased to over $50 million (up from $1.5 million a year prior). Headcount expanded to about 530 employees and the company reports a 0% loss rate across its lending portfolio since inception. BlockFi plans to launch a Bitcoin Rewards Credit Card, expand its product suite and global retail support (Europe, APAC, LatAm), pursue strategic acquisitions, and double headcount by year’s end. BlockFi is a cryptocurrency lender and financial services company based in Jersey City, NJ. It offers USD loans backed by crypto, interest-earning accounts, trading, and released iOS and Android mobile apps. The company is expanding into new business lines including an upcoming bitcoin rewards-based credit card and support for additional assets and currencies. BlockFi services clients worldwide and in all U.S. states, and has seen particularly strong growth in Asian markets aided by strategic partnerships. It reported more than $1.5B in assets on the platform and a 0% loss rate across its lending portfolio since inception. The firm has bolstered its leadership with hires including a Chief Growth Officer, Chief Security Officer, General Counsel, and a Europe/APAC Managing Director. BlockFi offers a suite of crypto financial products that seamlessly interact with one another. Its products include crypto-based interest accounts providing up to an 8.6% annual percentage yield on Bitcoin, Ether and stablecoins, crypto-backed loans allowing liquidity up to 50% of an asset's value, and zero-fee trading. The company reports more than $650M in assets on the platform and a 0% loss rate across its entire loan portfolio since it began lending in January 2018. BlockFi grew revenue more than 20x in 2019. On the institutional side it services over 50 reputable institutional clients and plans to open a Singapore office in the first half of 2020 to better serve Asia Pacific clients. Proceeds from the raise will be used to grow the team and expand offerings to mainstream users, starting with a mobile app in the coming months.